BioCentury
ARTICLE | Strategy

Genmab's deal-smything

May 14, 2001 7:00 AM UTC

An antibody deal between Genmab A/S and F. Hoffmann-La Roche Ltd. may have raised a few eyebrows last week among those who follow the spinout of Medarex Inc. (MEDX, Princeton, N.J.).

Genmab (CSE:GEN; NMarkt:GE9D, Copenhagen, Denmark) uses HuMAb and UltiMAb transgenic mouse technology licensed from MEDX to generate human monoclonal antibodies against targets it in-licenses or obtains from partner companies. Under a September 2000 license from MEDX, GEN was allowed to market the technology to partners in Europe with worldwide revenues under $1 billion, a description that obviously doesn't fit ROCZ (Basel, Switzerland), which is providing three disease targets for UltiMAb development (see BioCentury, Sept. 25, 2000). ...